Patents by Inventor Jonathan Henry Ellis

Jonathan Henry Ellis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treatment with humanized anti-IL-18 antibodies
    Patent number: 10703814
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 7, 2020
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • HUMANIZED ANTI-IL-18 ANTIBODIES
    Publication number: 20190031753
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: October 16, 2018
    Publication date: January 31, 2019
    Inventors: Jonathan Henry ELLIS, Volker Germaschewski, Paul Andrew Hamblin
  • IMMUNOGLOBULINS
    Publication number: 20170029497
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: October 14, 2016
    Publication date: February 2, 2017
    Inventors: Jonathan Henry ELLIS, Volker GERMASCHEWSKI, Paul Andrew HAMBLIN
  • Humanized anti-IL-18 antibodies
    Patent number: 9499617
    Abstract: The present invention discloses humanized anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 22, 2016
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20160207993
    Abstract: The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.
    Type: Application
    Filed: June 15, 2015
    Publication date: July 21, 2016
    Inventors: Claire ASHMAN, Thil Batuwangala, Michael Neil Burden, Stephanie Jane Clegg, Rudolf Maria De Wildt, Jonathan Henry Ellis, Paul Andrew Hamblin, Farhana Hussain, Laurent Jespers, Alan Lewis, Martin Anibal Orecchia, Radha Shah, Michael Steward
  • ANTIBODIES AGAINST AMYLOID-BETA PEPTIDE
    Publication number: 20160024197
    Abstract: Antibodies that bind human ?-amyloid peptide, methods of treating diseases or disorders characterised by elevated ?-amyloid levels or ?-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.
    Type: Application
    Filed: October 13, 2015
    Publication date: January 28, 2016
    Inventors: Stephen Anthony BURBIDGE, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden, Jonathan Henry Ellis, Susannah K Ford, Volker Germaschewski
  • Antibodies
    Patent number: 9193784
    Abstract: Antibodies that bind human ?-amyloid peptide, methods of treating diseases or disorders characterized by elevated ?-amyloid levels or ?-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 24, 2015
    Assignee: Glaxo Group Limited
    Inventors: Stephen Anthony Burbidge, Jonathan Henry Ellis, Susannah K Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • Humanized anti-beta-amyloid antibodies
    Patent number: 8921523
    Abstract: Antigen binding proteins that bind ?-amyloid peptide, in particular human ?-amyloid peptide; methods of treating diseases or disorders characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease and diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, including age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with the antigen binding proteins; pharmaceutical compositions comprising the antigen binding proteins; and methods of manufacture.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: December 30, 2014
    Assignee: Glaxo Group Limited
    Inventors: Philippe Marc Louis Alard, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Gerald Wayne Gough, Alan Peter Lewis, Peter Ernest Soden, Pamela Joan Thomas, Trevor Anthony Kenneth Wattam
  • Antigen binding proteins
    Patent number: 8858943
    Abstract: The present invention relates to methods of treating diseases or disorders affecting the eye or optic nerve characterized by elevated ?-amyloid levels or ?-amyloid deposits, particularly age related macular degeneration and glaucoma type diseases and ?-amyloid dependent cataract formation, with antigen binding proteins that bind ?-amyloid peptide and in particular human ?-amyloid peptide.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: October 14, 2014
    Assignee: Glaxo Group Limited
    Inventors: Stephen Anthony Burbidge, Ian Richard Catchpole, Jonathan Henry Ellis, Susannah Karen Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • NOGO-A Neutralizing Immunoglobulins for the Treatment of Neurological Diseases
    Publication number: 20140147435
    Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorders.
    Type: Application
    Filed: May 7, 2013
    Publication date: May 29, 2014
    Inventors: Jonathan Henry ELLIS, Paul Andrew Hamblin, Alan Peter Lewis, Paul Alexander Wilson
  • HUMANIZED ANTI-IL-18 ANTIBODIES
    Publication number: 20140105894
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: December 19, 2013
    Publication date: April 17, 2014
    Applicant: Glaxo Group Limited
    Inventors: Jonathan Henry ELLIS, Volker Germaschewski, Paul Andrew Hamblin
  • IL-13 binding protein
    Patent number: 8680245
    Abstract: The present invention relates to antigen binding proteins to human IL-13, including anti-IL-13 antibodies and anti-IL-3/anti-IL-4 mAbdAbs, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as asthma or IPF.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: March 25, 2014
    Assignee: Glaxo Group Limited
    Inventors: Claire Ashman, Jonathan Henry Ellis, Paul Andrew Hamblin, Alan Peter Lewis, Martin Anibal Orecchia
  • ANTIBODIES
    Publication number: 20140050719
    Abstract: Antibodies that bind human ?-amyloid peptide, methods of treating diseases or disorders characterised by elevated ?-amyloid levels or ?-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.
    Type: Application
    Filed: June 8, 2012
    Publication date: February 20, 2014
    Inventors: Stephen Anthony Burbidge, Jonathan Henry Ellis, Susannah K. Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • Humanized anti-IL-18 antibodies
    Patent number: 8637018
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: January 28, 2014
    Assignee: Glaxo Group Limited
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin
  • IMMUNOGLOBULINS
    Publication number: 20130287781
    Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing such antibodies and the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.
    Type: Application
    Filed: January 28, 2013
    Publication date: October 31, 2013
    Inventors: Stephanie Jane CLEGG, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabiner Kumar Prinjha
  • ANTIGEN-BINDING PROTEINS WITH INCREASED FCRN BINDING
    Publication number: 20130243764
    Abstract: The present invention provides antigen binding proteins which bind specifically to TNF-alpha. For example novel variants of anti-TNF antibodies such as adalimumab which show increased binding to the FcRn receptor or increased half life compared to adalimumab. Also provided are compositions comprising the antigen binding proteins and uses of such compositions in treatment of disorders and disease.
    Type: Application
    Filed: July 19, 2012
    Publication date: September 19, 2013
    Inventors: Jonathan Henry Ellis, Michael J. Molloy, Tejash Shah, Ian M. Tomlinson, Ahmed Yasin
  • Immunoglobulins
    Patent number: 8362208
    Abstract: The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: January 29, 2013
    Assignee: Glaxo Group Limited
    Inventors: Stephanie Jane Clegg, Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, George Kopsidas, Ruth McAdam, Rabinder Kumar Prinjha
  • NOVEL USES
    Publication number: 20120315267
    Abstract: The present invention relates to antibodies which multiple antigen specificities and their use in treating human diseases
    Type: Application
    Filed: February 9, 2011
    Publication date: December 13, 2012
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: Stephanie Jane Clegg, Eric Dobrzynski, Jonathan Henry Ellis, Volker Germaschewski, Alexis Paul Godillot, Zdenka Ludmila Jonak, Alan Peter Lewis, John Richard White
  • Antibodies against amyloid-? peptide
    Patent number: 8227576
    Abstract: Antibodies that bind human ?-amyloid peptide, methods of treating diseases or disorders characterised by elevated ?-amyloid levels or ?-amyloid deposits with said antibodies, pharmaceutical compositions comprising said antibodies and methods of manufacture.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: July 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Stephen Anthony Burbidge, Jonathan Henry Ellis, Susannah K Ford, Volker Germaschewski, Umesh Kumar, Karen Louise Philpott, Peter Ernest Soden
  • IMMUNOGLOBULINS
    Publication number: 20120100137
    Abstract: The present invention discloses humanised anti-IL-18 antibodies, methods of manufacture, and methods of treatment with said antibodies. Further disclosed are screening methods using for example surface plasmon resonance to identify antibodies with therapeutic potential.
    Type: Application
    Filed: December 9, 2011
    Publication date: April 26, 2012
    Inventors: Jonathan Henry Ellis, Volker Germaschewski, Paul Andrew Hamblin, Ian Kirby